No Data
Stifel Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $21
Analysts Have Conflicting Sentiments on These Healthcare Companies: Iovance Biotherapeutics (IOVA) and Madrigal Pharmaceuticals (MDGL)
Insider Stock Buying Reaches US$48.3m On Iovance Biotherapeutics
Is Iovance Biotherapeutics (IOVA) Among Billionaire Joseph Edelman's Long-Term Stock Picks?
Wells Fargo Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $25
Goldman Sachs Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $22